We have regulatory approval in the United Kingdom for a trial of erythrocyte-encapsulated thymidine phosphorylase (EE-TP), an enzyme replacement therapy for the treatment of MNGIE. This evidence concerns the gene TYMP and mitochondrial neurogastrointestinal encephalomyopathy.